Study Shows Survival Advantage of Primary Cytoreductive Surgery

(April 26, 2018) The International Journal of Gynecological Cancer recently featured a retrospective study on the treatment patterns of women with advanced high-grade serous ovarian carcinoma (HGSC). Of the 852 women with HGSC included in the study, 53% of them underwent primary cytoreductive surgery (PCS), or surgery before chemotherapy to remove as much of the tumor as possible, and 47% of them underwent neoadjuvant chemotherapy (NACT), or chemotherapy that takes place before surgery in order to reduce the size of the tumor first.

The 5 year overall survival (OS) for women treated with PCS was 3.89 years while women treated with NACT was 2.48 years. Although patients in both groups had a better OS when there was 0mm residual tumor, PCS patients who had 1 – 9mm residual had outcomes similar in OS as patients who underwent NACT with 0 mm residual.

The study concludes by recommending that women speak with their gynecologic oncologists about the possibility of being treated with PCS as opposed to NACT due to the better OS rate.

Posted on in Research